Organisation paid for research Program year 2025 Source: CMS Open Payments

CCM Clinical Research Group

Neither a doctor nor a teaching hospital

Research payments

$1,462,653

535 payments

Through program year 2025, CCM Clinical Research Group is reported as receiving $1,462,653 in research payments, across 535 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $312,866 4
2024 Research $60,665 3
2021 Research $3,562 1
2020 Research $247,742 55
2019 Research $837,818 472

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $1,067,813 516 payments
  2. E.R. Squibb & Sons, L.L.C. $373,531 7 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $21,308 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $683,056 326 payments
  2. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $213,215 2 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies $207,852 126 payments
  4. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $103,692 59 payments
  5. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $73,214 5 payments
  6. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $69,204 2 payments
  7. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $65,825 2 payments
  8. Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $25,288 1 payment
  9. BAY94-8862 ph 3 conventional in diabetic nephropathy $12,351 8 payments
  10. BAY 94-8862 ph 3 conventional in diab nephropathy $8,957 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record